

# Apolipoprotein C-III inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/A22C9A232D6CEN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: A22C9A232D6CEN

## Abstracts

This report can be delivered to the clients within 2-3 Business Days

DelveInsight's, "Apolipoprotein C-III inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Apolipoprotein C-III inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Apolipoprotein C-III inhibitors Understanding

#### Apolipoprotein C-III inhibitors: Overview

Apolipoprotein C-III (APOC3) is a key regulator of lipoprotein metabolism and plays a pivotal role in regulating plasma triglyceride levels. It is synthesized principally in the liver and is a component of triglyceride-rich lipoproteins. It is known to inhibit lipoprotein lipase-mediated hydrolysis of triglyceride-rich lipoproteins and to adversely affect receptor-mediated hepatic uptake of remnants of triglyceride-rich lipoproteins.

### Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Apolipoprotein C-III inhibitors R&D. The

therapies under development are focused on novel approaches for Apolipoprotein C-III inhibitors.

## Apolipoprotein C-III inhibitors Emerging Drugs Chapters

This segment of the Apolipoprotein C-III inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Apolipoprotein C-III inhibitors Emerging Drugs

### IONIS-APOCIII-LRx: Ionis Pharmaceuticals

IONIS-APOCIII-LRx, formerly known as AKCEA-APOCIII-LRx, is a ligand-conjugated (LICA) investigational antisense medicine designed to inhibit the production of apoC-III, for patients who are at risk of disease due to elevated triglyceride levels. ApoC-III is a protein produced in the liver that regulates triglyceride metabolism in the blood. People with severely elevated triglycerides, such as people with familial chylomicronemia syndrome (FCS), are at high risk for acute pancreatitis and other serious conditions. ApoC-III is also the target of WAYLIVRA, the first approved medicine for patients with FCS.

### ARO-APOC3: Arrowhead Pharmaceuticals,

ARO-APOC3 is designed to reduce production of Apolipoprotein C-III (apoC-III), a component of triglyceride rich lipoproteins (TRLs) including VLDL and chylomicrons and is a key regulator of triglyceride metabolism. The company believes that knocking down the hepatic production of apoC-III may result in reduced VLDL synthesis and assembly, enhanced breakdown of TRLs, and better clearance of VLDL and chylomicron remnants.

Further product details are provided in the report.....

## Apolipoprotein C-III inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Apolipoprotein C-III inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Apolipoprotein C-III inhibitors

There are approx. 3+ key companies which are developing the Apolipoprotein C-III inhibitors. The companies which have their Apolipoprotein C-III inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Ionis Pharmaceuticals.

Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Apolipoprotein C-III inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Apolipoprotein C-III inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Apolipoprotein C-III inhibitors

therapeutic drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Apolipoprotein C-III inhibitors drugs.

### Apolipoprotein C-III inhibitors Report Insights

Apolipoprotein C-III inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

### Apolipoprotein C-III inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

### Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Apolipoprotein C-III inhibitors drugs?

How many Apolipoprotein C-III inhibitors drugs are developed by each

company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Apolipoprotein C-III inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Apolipoprotein C-III inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Apolipoprotein C-III inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Ionis Pharmaceuticals

Arrowhead Pharmaceuticals

argenx

Korea United Pharm I

## Key Products

IONIS-APOCIII-LRx

Volanesorsen

ARO APOC3

ARGX 116

UI 014

## Contents

- Introduction
- Executive Summary
- Apolipoprotein C-III inhibitors: Overview
  - Structure
  - Mechanism of Action
- Pipeline Therapeutics
  - Comparative Analysis
- Therapeutic Assessment
  - Assessment by Product Type
  - Assessment by Stage and Product Type
  - Assessment by Route of Administration
  - Assessment by Stage and Route of Administration
  - Assessment by Molecule Type
  - Assessment by Stage and Molecule Type
- Apolipoprotein C-III inhibitors – DelveInsight's Analytical Perspective
- Late Stage Products (Phase III)
  - Comparative Analysis
- IONIS-APOCIII-LRx: Ionis Pharmaceuticals
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
  - Comparative Analysis
- ARO APOC3: Arrowhead Pharmaceuticals
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I)
  - Comparative Analysis
- ARGX 116: argenx
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....
- Pre-clinical and Discovery Stage Products



Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Apolipoprotein C-III inhibitors Key Companies

Apolipoprotein C-III inhibitors Key Products

Apolipoprotein C-III inhibitors- Unmet Needs

Apolipoprotein C-III inhibitors- Market Drivers and Barriers

Apolipoprotein C-III inhibitors- Future Perspectives and Conclusion

Apolipoprotein C-III inhibitors Analyst Views

Apolipoprotein C-III inhibitors Key Companies

Appendix

## I would like to order

Product name: Apolipoprotein C-III inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/A22C9A232D6CEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A22C9A232D6CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970